GLS

EBA consults on draft technical standards on complaints handling procedures under the Markets in Crypto-Assets Regulation

Retrieved on: 
Thursday, July 13, 2023
Crypto, Review, Insurance, Reformed Churches in the Netherlands (Liberated), European Banking Authority, The, Caspe, Policy, European Securities and Markets Authority, Article, EBA, Joint committee, Market, Investment, European, GLS, Emergency medical technician, ESMA, JC, RTS, Cryptocurrency, Security (finance), Property management, EU

12 July 2023

Key Points: 
  • 12 July 2023
    The European Banking Authority (EBA) published today a Consultation Paper on draft regulatory technical standards (RTS) on complaints handling procedures for issuers of asset-referenced tokens (ARTs) under the Markets in Crypto-Assets Regulation (MiCAR).
  • These draft RTS aim at ensuring prompt, fair and consistent handling of complaints by holders of ARTs and other interested parties.
  • The EBA is mandated to develop, in close cooperation with the European Securities and Market Authority (ESMA), draft RTS on the complaints handling procedures of issuers of ARTs.
  • The consultation paper on complaints handling is published on the same date as consultation papers on authorisations and qualifying holdings.

Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®

Retrieved on: 
Thursday, June 22, 2023
Luxury, Women, Clinical Trials, Biotechnology, Health, Cosmetics, Consumer, General Health, Retail, Botulinum toxin, Interim, Sale, Trial of the century, Congress, Development, Data, Patient, GLS, World Congress, Safety, Pharmaceutical industry, Research

Presentation of the full dataset will be planned for a medical meeting in Q4 2023.

Key Points: 
  • Presentation of the full dataset will be planned for a medical meeting in Q4 2023.
  • “Concluding this Phase 2 clinical study marks another significant milestone for Evolus and our commitment to delivering continued product innovation,” said Rui Avelar, M.D., Chief Medical Officer and Head of Research and Development, Evolus.
  • The study has three arms: Jeuveau Extra-Strength 40U and two active controls, BOTOX® 20U and Jeuveau 20U.
  • Through the company’s TRANSPARENCY Clinical Program, Jeuveau was clinically proven to temporarily improve moderate to severe glabellar lines or “11’s” in adults and included the largest head-to-head pivotal study versus BOTOX®.

KBRA Assigns Preliminary Ratings to GLS Auto Select Receivables Trust 2023-1

Retrieved on: 
Monday, June 5, 2023
Other Professional Services, Professional Services, Finance, KBRA, GLS, Insurance, ABS, Assured Investment Management, Security (finance), Telescopic sight

KBRA assigns preliminary ratings to six classes of notes issued by GLS Auto Select Receivables Trust 2023-1 (“GSAR 2023-1”), a near prime auto loan ABS transaction.

Key Points: 
  • KBRA assigns preliminary ratings to six classes of notes issued by GLS Auto Select Receivables Trust 2023-1 (“GSAR 2023-1”), a near prime auto loan ABS transaction.
  • The Company has also issued 23 securitizations, collateralized by mostly subprime auto loans, since its inaugural issuance in 2014.
  • The Company began originating subprime loans in 2013 and near prime loans via the “Select Program” in October 2021.
  • KBRA considered its operation review of GLS, as well as periodic due diligence calls with GLS.

The GLS North American Vision

Retrieved on: 
Tuesday, May 30, 2023
GLS Group, GLS, Logistics, LTL, Transport, Acquisition, Golden, Airline, Video game, Parcel

GLS continues to expand its network and enhance its service offering with the goal of connecting people across North America and around the world.

Key Points: 
  • GLS continues to expand its network and enhance its service offering with the goal of connecting people across North America and around the world.
  • Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9163851-the-gls-north-american-v...
    Although the name GLS may be new in North America, our roots in both the United States and Canada are deep having combined five well-established and long-standing companies to create GLS in North America.
  • GLS Group is one of the largest parcel services providers in Europe, with a strong local presence across the continent.
  • What's next for GLS in North America?

KBRA Assigns Preliminary Ratings to GLS Auto Receivables Issuer Trust 2023-2

Retrieved on: 
Thursday, May 4, 2023
Banking, Professional Services, Finance, Insurance, KBRA, ABS, Car, Assured Investment Management, GLS, Security (finance), Telescopic sight

KBRA assigns preliminary ratings to six classes of notes issued by GLS Auto Receivables Issuer Trust 2023-2 (“GCAR 2023-2”), an auto loan ABS transaction.

Key Points: 
  • KBRA assigns preliminary ratings to six classes of notes issued by GLS Auto Receivables Issuer Trust 2023-2 (“GCAR 2023-2”), an auto loan ABS transaction.
  • GCAR 2023-2 represents the second term ABS securitization for Global Lending Services, LLC (“GLS” or the “Company”) in 2023 and the 23rd overall.
  • GLS is a subprime auto finance company founded in 2011 and is majority-owned by Assured Investment Management LLC (“Assured”), an alternative asset manager owned by funds managed by Assured Guaranty Ltd, an insurance company.
  • KBRA considered its operation review of GLS, as well as periodic due diligence calls with GLS.

The innovative echocardiography software platform "CAAS Qardia" by Pie Medical Imaging receives medical device certification in Japan

Retrieved on: 
Monday, April 24, 2023
CAAS, Web browser, E20, Certification, Journal, GLS, Assessment, Echocardiography, Automation, Medical imaging, Nursing, Medical device

MAASTRICHT, Netherlands, April 24, 2023 /PRNewswire/ -- Pie Medical Imaging, a global leader in cardiac imaging, announced it has received NINSHO Medical Device Certification for CAAS Qardia, their innovative echocardiography software platform.

Key Points: 
  • MAASTRICHT, Netherlands, April 24, 2023 /PRNewswire/ -- Pie Medical Imaging, a global leader in cardiac imaging, announced it has received NINSHO Medical Device Certification for CAAS Qardia, their innovative echocardiography software platform.
  • CAAS Qardia excels at myocardial strain analysis, stress-echo, diastolic function assessment, and (PISA) valve analysis.
  • René Guillaume, Managing Director of Pie Medical Imaging said: "With this certification of CAAS Qardia, an easy-to-use and accurate tool becomes available for Japanese healthcare institutions."
  • "Echocardiography Core Laboratory Validation of a Novel Vendor-Independent Web-Based Software for the Assessment of Left Ventricular Global Longitudinal Strain".

GLS Canada begins its first fully electric last mile deliveries, another step towards the company's ambition of zero emissions by 2045

Retrieved on: 
Thursday, April 20, 2023
Carbon footprint, LEED, Greenhouse gas, GHG, City, Sustainability, Gold, GLS Group, GLS, Knowledge, Lion Electric Company, Sustainable development, Phoenix Mobility Program, Western Canada

It brings us joy to support a local business and promote the local economy all while reducing our carbon footprint," Rick Barnes, President of GLS Canada.

Key Points: 
  • It brings us joy to support a local business and promote the local economy all while reducing our carbon footprint," Rick Barnes, President of GLS Canada.
  • These four zero-emission trucks will replace the current diesel trucks operated by GLS Canada.
  • GLS Canada continues to work towards the ambition of zero emission as the recipient of the City of Montreal's Sustainable Development and Mobility Program.
  • Strongly supported by GLS Group's experience, GLS Canada's environmental plan places primary emphasis on emission reduction and avoidance with the long-term ambition of zero emissions by 2045.

Sight Sciences Appoints Ali Bauerlein as Chief Financial Officer

Retrieved on: 
Monday, April 3, 2023
Treasury, University, Risk management, Securities and Exchange Commission of Pakistan, Forecasting, Patient, GLS, Growth, Therapy, Audit committee, NYSE, Management

MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces the appointment of Alison “Ali” Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023.

Key Points: 
  • MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces the appointment of Alison “Ali” Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023.
  • “I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth.
  • Her experience and talent will provide an immediate and valuable impact,” said Paul Badawi, co-founder and Chief Executive Officer of Sight Sciences.
  • Ms. Bauerlein cofounded Inogen in 2001 and served as its Chief Financial Officer from 2009 through 2021.

NYSE to Suspend Trading Immediately in Gelesis Holdings, Inc. (GLS) and Commence Delisting Proceedings

Retrieved on: 
Monday, April 10, 2023
Professional Services, Finance, Exchange, Securities and Exchange Commission (Nigeria), Committee, GLS, New York Stock Exchange, Security (finance), NYSE, Cryptocurrency

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Gelesis Holdings, Inc. (the “Company”) — ticker symbol GLS — from the NYSE.

Key Points: 
  • The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Gelesis Holdings, Inc. (the “Company”) — ticker symbol GLS — from the NYSE.
  • Trading in the Company’s common stock will be suspended immediately.
  • The Company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange.
  • The NYSE will apply to the Securities and Exchange Commission to delist the common stock upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

AMWC 2023: Data From Sculptra® Cheek Wrinkle and Alluzience® Star Studies Reinforce Strength of Galderma’s Broad Aesthetic Portfolio

Retrieved on: 
Thursday, March 30, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Patient satisfaction, STAR, Lifting, HIT, Science, Congress, Dermatology, Patient, GLS, Aesthetics, Cheek, Safety, RTU, Skin, AB toxin, Pharmaceutical industry, Cosmetics, Silviculture, Galderma, Sculptra

Galderma will be presenting the latest data from the Sculptra® (injectable poly-L-lactic acid, PLLA-SCA) Cheek Wrinkle and Alluzience® (abobotulinumtoxinA solution) STAR studies at the 21st Aesthetic & Anti-Aging Medical World (AMWC) Congress, taking place in Monaco, from March 30 to April 1, 2023.

Key Points: 
  • Galderma will be presenting the latest data from the Sculptra® (injectable poly-L-lactic acid, PLLA-SCA) Cheek Wrinkle and Alluzience® (abobotulinumtoxinA solution) STAR studies at the 21st Aesthetic & Anti-Aging Medical World (AMWC) Congress, taking place in Monaco, from March 30 to April 1, 2023.
  • At months seven to 12, those treated with Sculptra also had improved dynamic wrinkles, and even greater proportions had improved aesthetic appearance (≥93%), improved radiance, skin tightness, and jawline contour (≥86%).
  • At month six, most subjects felt that they looked natural (95%) and refreshed (85%) and were satisfied with their appearance (88%).
  • The event will take place on Thursday, March 30 at 2:00 PM in the Prince Pierre Auditorium.